Similarly, a significant elevation in BAX/BCL2 ratio to reach 9.43, 9.76, and 4.69 folds, respectively, was observed in hepatic cancer cell lines treated with doxorubicin 200 μm or sitagliptin (IC50: 89 μM; or IC35; 62.5 μM) as compared to the negative control, untreated cancer cell lines. This evidence concerns the gene BCL2 and liver cancer.